The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 04, 2025

Filed:

Jan. 13, 2023
Applicant:

Janssen Pharmaceuticals, Inc., Titusville, NJ (US);

Inventors:

Kurt Iver Kamrud, Olathe, KS (US);

Nathaniel Stephen Wang, San Diego, CA (US);

Martina Felderman, La Jolla, CA (US);

Nancy C. Carrico, La Jolla, CA (US);

Assignee:

Janssen Pharmaceuticals, Inc., Titusville, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); A61K 48/00 (2006.01); C07K 14/005 (2006.01); C07K 16/32 (2006.01); C12P 21/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 48/005 (2013.01); C07K 14/005 (2013.01); C07K 16/32 (2013.01); C12P 21/00 (2013.01); C07K 2317/14 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2319/00 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/18522 (2013.01); C12N 2770/10021 (2013.01); C12N 2770/10043 (2013.01);
Abstract

The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.


Find Patent Forward Citations

Loading…